OPUS GENETICS INC (IRD) Fundamental Analysis & Valuation

NASDAQ:IRD • US67577R1023

Current stock price

4.66 USD
-0.14 (-2.92%)
At close:
4.6 USD
-0.06 (-1.29%)
After Hours:

This IRD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. IRD Profitability Analysis

1.1 Basic Checks

  • In the past year IRD has reported negative net income.
  • In the past year IRD has reported a negative cash flow from operations.
  • In the past 5 years IRD reported 4 times negative net income.
  • In the past 5 years IRD reported 4 times negative operating cash flow.
IRD Yearly Net Income VS EBIT VS OCF VS FCFIRD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -188.81%, IRD is doing worse than 87.64% of the companies in the same industry.
  • IRD has a Return On Equity of -1143.00%. This is amonst the worse of the industry: IRD underperforms 81.27% of its industry peers.
Industry RankSector Rank
ROA -188.81%
ROE -1143%
ROIC N/A
ROA(3y)-46.02%
ROA(5y)-98.94%
ROE(3y)-68.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IRD Yearly ROA, ROE, ROICIRD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

1.3 Margins

  • IRD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IRD Yearly Profit, Operating, Gross MarginsIRD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. IRD Health Analysis

2.1 Basic Checks

  • IRD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • IRD has more shares outstanding than it did 1 year ago.
  • IRD has more shares outstanding than it did 5 years ago.
  • IRD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IRD Yearly Shares OutstandingIRD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
IRD Yearly Total Debt VS Total AssetsIRD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • IRD has an Altman-Z score of -2.60. This is a bad value and indicates that IRD is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -2.60, IRD perfoms like the industry average, outperforming 46.72% of the companies in the same industry.
  • A Debt/Equity ratio of 0.18 indicates that IRD is not too dependend on debt financing.
  • IRD has a worse Debt to Equity ratio (0.18) than 65.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Altman-Z -2.6
ROIC/WACCN/A
WACC8.84%
IRD Yearly LT Debt VS Equity VS FCFIRD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 1.23 indicates that IRD should not have too much problems paying its short term obligations.
  • IRD has a Current ratio of 1.23. This is amonst the worse of the industry: IRD underperforms 84.36% of its industry peers.
  • IRD has a Quick Ratio of 1.23. This is a normal value and indicates that IRD is financially healthy and should not expect problems in meeting its short term obligations.
  • IRD has a Quick ratio of 1.23. This is amonst the worse of the industry: IRD underperforms 83.78% of its industry peers.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.23
IRD Yearly Current Assets VS Current LiabilitesIRD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. IRD Growth Analysis

3.1 Past

  • IRD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.85%, which is quite impressive.
  • The Revenue has grown by 74.60% in the past year. This is a very strong growth!
  • Measured over the past years, IRD shows a very strong growth in Revenue. The Revenue has been growing by 165.10% on average per year.
EPS 1Y (TTM)23.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.79%
Revenue 1Y (TTM)74.6%
Revenue growth 3Y165.1%
Revenue growth 5YN/A
Sales Q2Q%-20.38%

3.2 Future

  • IRD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.10% yearly.
  • Based on estimates for the next years, IRD will show a very strong growth in Revenue. The Revenue will grow by 87.95% on average per year.
EPS Next Y38.1%
EPS Next 2Y25.77%
EPS Next 3Y16.53%
EPS Next 5Y11.1%
Revenue Next Year48.39%
Revenue Next 2Y36.77%
Revenue Next 3Y27.79%
Revenue Next 5Y87.95%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
IRD Yearly Revenue VS EstimatesIRD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
IRD Yearly EPS VS EstimatesIRD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20 -30 -40

More info and screens

Find the best growth stocksShow best growing peers

0

4. IRD Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IRD. In the last year negative earnings were reported.
  • Also next year IRD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IRD Price Earnings VS Forward Price EarningsIRD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IRD Per share dataIRD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

  • IRD's earnings are expected to grow with 16.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.77%
EPS Next 3Y16.53%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IRD Dividend Analysis

5.1 Amount

  • IRD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IRD Fundamentals: All Metrics, Ratios and Statistics

OPUS GENETICS INC

NASDAQ:IRD (3/18/2026, 8:16:24 PM)

After market: 4.6 -0.06 (-1.29%)

4.66

-0.14 (-2.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-30
Inst Owners34.04%
Inst Owner ChangeN/A
Ins Owners9.68%
Ins Owner Change-13.22%
Market Cap321.35M
Revenue(TTM)14.63M
Net Income(TTM)-68.20M
Analysts82.5
Price Target7.88 (69.1%)
Short Float %2.12%
Short Ratio1.12
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-24.18%
Min EPS beat(2)-90.4%
Max EPS beat(2)42.04%
EPS beat(4)3
Avg EPS beat(4)-7.07%
Min EPS beat(4)-90.4%
Max EPS beat(4)42.04%
EPS beat(8)3
Avg EPS beat(8)-59.5%
EPS beat(12)5
Avg EPS beat(12)-24%
EPS beat(16)8
Avg EPS beat(16)-16.12%
Revenue beat(2)0
Avg Revenue beat(2)-15.16%
Min Revenue beat(2)-29.45%
Max Revenue beat(2)-0.87%
Revenue beat(4)2
Avg Revenue beat(4)12.9%
Min Revenue beat(4)-29.45%
Max Revenue beat(4)42.31%
Revenue beat(8)3
Avg Revenue beat(8)-8.15%
Revenue beat(12)6
Avg Revenue beat(12)22.35%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.79%
EPS NQ rev (1m)-0.31%
EPS NQ rev (3m)11.47%
EPS NY rev (1m)-0.03%
EPS NY rev (3m)4.85%
Revenue NQ rev (1m)-1%
Revenue NQ rev (3m)-6.98%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)-0.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 21.96
P/FCF N/A
P/OCF N/A
P/B 53.86
P/tB 53.86
EV/EBITDA N/A
EPS(TTM)-0.83
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS0.21
BVpS0.09
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -188.81%
ROE -1143%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.02%
ROA(5y)-98.94%
ROE(3y)-68.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 1.23
Altman-Z -2.6
F-Score2
WACC8.84%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.79%
EPS Next Y38.1%
EPS Next 2Y25.77%
EPS Next 3Y16.53%
EPS Next 5Y11.1%
Revenue 1Y (TTM)74.6%
Revenue growth 3Y165.1%
Revenue growth 5YN/A
Sales Q2Q%-20.38%
Revenue Next Year48.39%
Revenue Next 2Y36.77%
Revenue Next 3Y27.79%
Revenue Next 5Y87.95%
EBIT growth 1Y-25.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year128.22%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-242.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-242.06%
OCF growth 3YN/A
OCF growth 5YN/A

OPUS GENETICS INC / IRD Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for OPUS GENETICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to IRD.


Can you provide the valuation status for OPUS GENETICS INC?

ChartMill assigns a valuation rating of 0 / 10 to OPUS GENETICS INC (IRD). This can be considered as Overvalued.


How profitable is OPUS GENETICS INC (IRD) stock?

OPUS GENETICS INC (IRD) has a profitability rating of 0 / 10.


What is the financial health of OPUS GENETICS INC (IRD) stock?

The financial health rating of OPUS GENETICS INC (IRD) is 2 / 10.